英文名稱 |
中文名稱 |
CAS號 |
操作 |
TL02-59 |
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide |
1315330-17-6 |
詳細(xì)
|
WRG-28 |
WRG-28 |
1913291-02-7 |
詳細(xì)
|
FGFR1/DDR2 inhibitor 1 |
FGFR1/DDR2 inhibitor 1 |
2308497-58-5 |
詳細(xì)
|
SRI 31215 TFA |
SRI-31215 BIS-TFA SALT |
1832686-44-8 |
詳細(xì)
|
CLK-IN-T3 |
CLK inhibitor T3
(T3) |
2109805-56-1 |
詳細(xì)
|
MAZ51 |
CS-2885 |
163655-37-6 |
詳細(xì)
|
AZD7507 |
CS-2850 |
1041852-85-0 |
詳細(xì)
|
JH-VIII-157-02 |
化合物 T15612 |
1639422-97-1 |
詳細(xì)
|
PRN1008 |
瑞扎布魯替尼 |
1575596-29-0 |
詳細(xì)
|
ARQ 531 |
ARQ-531 |
2095393-15-8 |
詳細(xì)
|
TIE-2/VEGFR-2 kinase-IN-1 |
6-(4-甲氧基苯基)呋喃并[2,3-D]嘧啶-4-胺 |
453590-24-4 |
詳細(xì)
|
Pralsetinib |
BLU-667(拉西替尼) |
2097132-94-8 |
詳細(xì)
|
trans-Pralsetinib |
cis-Pralsetinib hydrochloride (cis-BLU-667 hydrochloride) |
2097132-93-7 |
詳細(xì)
|
cFMS Receptor Inhibitor II |
CFMS RECEPTOR INHIBITOR II |
959860-85-6 |
詳細(xì)
|
AGL-2263 |
AG 2263 |
638213-98-6 |
詳細(xì)
|
AZD3229 Tosylate |
AZD3229 Tosylate |
2248003-71-4 |
詳細(xì)
|
SPP-86 |
1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
1357349-91-7 |
詳細(xì)
|
BMS-509744 |
N-(5-((5-(4-乙?;哙?1-甲?;?-4-甲氧基-2-甲基苯基)硫基)噻唑-2-基)-4-(((3,3-二甲基丁烷-2-基)氨基)甲基)苯甲酰胺 |
439575-02-7 |
詳細(xì)
|
JNJ-38877618 |
JNJ-38877618 |
943540-74-7 |
詳細(xì)
|
FN-1501 |
1429515-59-2 |
1429515-59-2 |
詳細(xì)
|
PDGFRα kinase inhibitor 1 |
PDGFRα kinase inhibitor 1 |
2209053-93-8 |
詳細(xì)
|
Jaspamycin |
JASPAMYCIN |
22242-96-2 |
詳細(xì)
|
Nintedanib Ethanesulfonate Salt |
尼達(dá)尼布乙磺酸鹽 |
656247-18-6 |
詳細(xì)
|
AZ-Dyrk1B-33 |
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine |
1679330-37-0 |
詳細(xì)
|
RU-301 |
RU-301 |
1110873-99-8 |
詳細(xì)
|
Tyrphostin AG1433 |
Tyrphostin AG1433 |
168835-90-3 |
詳細(xì)
|
Pazopanib Hydrochloride |
鹽酸帕唑帕尼 |
635702-64-6 |
詳細(xì)
|
PF-04217903 methanesulfonate |
PF 04217903 MESYLATE |
956906-93-7 |
詳細(xì)
|
Lyn-IN-1 |
巴非替尼 |
887650-05-7 |
詳細(xì)
|
Cabozantinib S-malate |
蘋果酸卡博替尼 |
1140909-48-3 |
詳細(xì)
|
Pivanex |
(2,2-二甲基-1-氧代丙氧基)丁酸甲酯 |
122110-53-6 |
詳細(xì)
|
R406 |
6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-惡嗪-3(4H)-酮苯磺酸鹽 |
841290-81-1 |
詳細(xì)
|
DPH |
5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮 |
484049-04-9 |
詳細(xì)
|
Lck Inhibitor |
6-(2,6-二甲基苯基)-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-嘧啶并[5',4':5,6]嘧啶并[1,2-A]苯并咪唑-5(6H)-酮 |
847950-09-8 |
詳細(xì)
|
UNC2025 hydrochloride |
UNC2025 鹽酸鹽 |
2070015-17-5 |
詳細(xì)
|
TAS-115 mesylate |
TAS-115 MESYLATE |
1688673-09-7 |
詳細(xì)
|
Gilteritinib hemifumarate |
GILTERITINIB FUMARATE |
1254053-84-3 |
詳細(xì)
|
BT-13 |
BT-13 |
924537-98-4 |
詳細(xì)
|
Y15 |
1,2,4,5-苯四胺四鹽酸鹽 |
4506-66-5 |
詳細(xì)
|
Bozitinib |
BOZITINIB (PLB-1001) |
1440964-89-5 |
詳細(xì)
|
Hck-IN-1 |
Nef-IN-B9 |
1473404-51-1 |
詳細(xì)
|
UNC2541 |
UNC2541 |
1612782-86-1 |
詳細(xì)
|
TAM-IN-2 |
TAM-IN-2 |
2135642-56-5 |
詳細(xì)
|
Petunidin chloride |
矮牽牛素PT |
1429-30-7 |
詳細(xì)
|
Syk-IN-1 |
1,2,4-Triazine-6-carboxamide, 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(1H-indol-7-ylamino)- |
1491150-77-6 |
詳細(xì)
|
PRN694 |
1575818-46-0 |
1575818-46-0 |
詳細(xì)
|
Mirk-IN-1 |
1386979-55-0 |
1386979-55-0 |
詳細(xì)
|
Brigatinib |
布格替尼 |
1197953-54-0 |
詳細(xì)
|
Remibrutinib |
LOU-064 |
1787294-07-8 |
詳細(xì)
|
Orelabrutinib |
奧布替尼 |
1655504-04-3 |
詳細(xì)
|
SKLB4771 |
FLT3-IN-1 |
1370256-78-2 |
詳細(xì)
|
Dubermatinib |
TP-0903 |
1341200-45-0 |
詳細(xì)
|
S49076 |
CS-2684 |
1265965-22-7 |
詳細(xì)
|
PRT-060318 |
PRT-060318 |
1194961-19-7 |
詳細(xì)
|
Alectinib Hydrochloride |
艾樂替尼鹽酸鹽 |
1256589-74-8 |
詳細(xì)
|
Src Inhibitor 3 |
Src Inhibitor 3 |
2380027-49-4 |
詳細(xì)
|
(Rac)-IBT6A |
1412418-47-3 |
1412418-47-3 |
詳細(xì)
|
Fostamatinib |
福他替尼 |
901119-35-5 |
詳細(xì)
|
Fostamatinib disodium hexahydrate |
福他替尼鈉鹽水合物 |
914295-16-2 |
詳細(xì)
|
Cediranib maleate |
西地尼布馬來酸鹽 |
857036-77-2 |
詳細(xì)
|
Taletrectinib |
DS-6051b |
1505515-69-4 |
詳細(xì)
|
BIIB068 |
BIIB068 |
1798787-27-5 |
詳細(xì)
|
VEGFR-2-IN-6 |
帕唑帕尼雜質(zhì)3 |
444731-47-9 |
詳細(xì)
|
NVP-BHG712 isomer |
NVP-BHG712 isomer |
2245892-85-5 |
詳細(xì)
|
MK-8033 |
MK-8033 |
1001917-37-8 |
詳細(xì)
|
MK-8033 hydrochloride |
3-(1-甲基-1H-吡唑-4-基)-5-氧代-N-(2-吡啶基甲基)-5H-苯并[4,5]環(huán)庚三烯并[1,2-B]吡啶-7-甲烷磺酰胺鹽酸鹽 |
1283000-43-0 |
詳細(xì)
|
CP-547632 |
3-[(4-溴-2,6-二氟芐基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]異噻唑-4-甲酰胺 |
252003-65-9 |
詳細(xì)
|
CP-547632 hydrochloride |
CP-547632 (hydrochloride) |
252003-71-7 |
詳細(xì)
|
BAY-474 |
化合物BAY-474 |
1033767-86-0 |
詳細(xì)
|
Infigratinib phosphate |
NVP BGJ398 磷酸鹽 |
1310746-10-1 |
詳細(xì)
|
RET-IN-3 |
化合物 RET-IN-3 |
2414374-53-9 |
詳細(xì)
|
LDN-192960 |
3-[(2,7-二甲氧基吖啶-9-基)硫基]丙胺 |
184582-62-5 |
詳細(xì)
|
LDN-192960 hydrochloride |
LDN-192960 HYDROCHLORIDE |
2309172-48-1 |
詳細(xì)
|
AC710 |
N-[4-[[[[5-(叔丁基)-3-異惡唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 |
1351522-04-7 |
詳細(xì)
|
Nocodazole |
諾考達(dá)唑 |
31430-18-9 |
詳細(xì)
|
CH6953755 |
CH6953755 |
2055918-71-1 |
詳細(xì)
|
CA-4948 |
4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)- |
1801344-14-8 |
詳細(xì)
|
AZM475271 |
476159-98-5 |
476159-98-5 |
詳細(xì)
|
I-OMe-Tyrphostin AG 538 |
I-OME-AG 538 |
1094048-77-7 |
詳細(xì)
|
BO-264 |
BO-264 |
2408648-20-2 |
詳細(xì)
|
DCC-3014 |
DCC3014 |
1628606-05-2 |
詳細(xì)
|
RET V804M-IN-1 |
化合物RET V804M-IN-1 |
2414909-94-5 |
詳細(xì)
|
PLX647 |
10MG |
873786-09-5 |
詳細(xì)
|
Flumatinib mesylate |
甲磺酸氟馬替尼/氟馬替尼 |
895519-91-2 |
詳細(xì)
|
VC-4718 |
PND1186 |
1061353-68-1 |
詳細(xì)
|
1-Naphthyl PP1 hydrochloride |
1-叔丁基-3-(1-萘基)-1H-吡唑并[3,4-D]嘧啶-4-胺鹽酸鹽 |
956025-47-1 |
詳細(xì)
|
DDR1-IN-1 |
N-[3-[(2,3-二氫-2-氧代-1H-吲哚-5-基)氧基]-4-甲基苯基]-4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯甲酰胺 |
1449685-96-4 |
詳細(xì)
|
PF-03814735 |
N-[2-[(1S,4R)-6-[[4-(環(huán)丁基氨基)-5-(三氟甲基)-2-嘧啶基]氨基]-1,2,3,4-四氫萘-1,4-亞氨-9-基]-2-氧代乙基]乙酰胺 |
942487-16-3 |
詳細(xì)
|
BAY 61-3606 dihydrochloride |
BAY 61-3606 |
648903-57-5 |
詳細(xì)
|
PRT062607 Hydrochloride |
PRT062607 (HYDROCHLORIDE) |
1370261-97-4 |
詳細(xì)
|
ALK inhibitor 1 |
2-[[5-溴-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 |
761436-81-1 |
詳細(xì)
|
ALK inhibitor 2 |
2-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 |
761438-38-4 |
詳細(xì)
|
Lucitanib |
德立替尼 |
1058137-23-7 |
詳細(xì)
|
GDC-0834 |
CS-1263 |
1133432-49-1 |
詳細(xì)
|
Imatinib D4 |
[2H4]-伊馬替尼 |
1134803-16-9 |
詳細(xì)
|
AG-13958 |
N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺 |
319460-94-1 |
詳細(xì)
|
GDC-0834 Racemate |
N-[3-[6-[[4-(1,4-二甲基-3-氧代-2-哌嗪基)苯基]氨基]-4,5-二氫-4-甲基-5-氧代-2-吡嗪基]-2-甲基苯基]-4,5,6,7-四氫苯并[B]噻吩-2-甲酰胺 |
1133432-46-8 |
詳細(xì)
|
GDC-0834 S-enantiomer |
化合物 T11378 |
1133432-50-4 |
詳細(xì)
|
Imatinib |
伊馬替尼 |
152459-95-5 |
詳細(xì)
|
Imatinib D8 |
伊馬替尼D8 |
1092942-82-9 |
詳細(xì)
|